/
SILO
$6.19+$0.15 (+2.40%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.6M
1M shares
52-week range
$3.32 – $15.15
24% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
38.67%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-100.69
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $40.6K | $0 | $71.3K | $72.1K | $72.1K | $72.1K | $72.1K |
| Cost of revenue | $17.6K | $27.4K | $0 | $5.0K | $5.8K | $5.8K | $5.8K | $886.1K |
| Gross profit | −$17.6K | $13.2K | $0 | $66.3K | $66.3K | $66.3K | $66.3K | −$814.0K |
| Gross margin | — | 32.5% | — | 93.0% | 91.9% | 91.9% | 91.9% | -1128.9% |
| R&D | $0 | $63.5K | $26.3K | $693.9K | $1.3M | $845.1K | $2.4M | $2.2M |
| Operating income | −$594.2K | −$930.4K | −$2.2M | −$2.7M | −$3.6M | −$3.9M | −$4.7M | −$4.3M |
| EBITDA | −$951.9K | −$950.4K | −$2.4M | $4.2M | −$3.9M | −$3.6M | −$4.4M | −$4.2M |
| Net income | −$969.5K | −$1.0M | −$3.0M | $3.9M | −$3.9M | −$3.7M | −$4.4M | −$4.2M |
| Net margin | — | -2497.7% | — | 5477.9% | -5420.9% | -5132.6% | -6092.6% | -5863.5% |
| EPS (diluted) | -14.85 | -18.60 | -35.25 | 19.50 | -25.65 | -18.00 | -17.85 | -7.50 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $72000 | $-10.80 | $-10.80–$-10.80 | 1 |
| 2027 | $72000 | $-16.80 | $-16.80–$-16.80 | 1 |
| 2028 | $72000 | $-18.15 | $-18.15–$-18.15 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.47
Price
$6.19
Implied upside
+4%
Peer comparison
Silo Pharma, Inc. Common Stock
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
www.silopharma.com- Employees
- 3
- IPO / List date
- Jan 5, 2012
- HQ
- SARASOTA, FL
Held by traders on TradeandTell
No one on the platform currently holds SILO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in SILO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-03 | 1-for-15reverse |
| 2022-09-15 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded SILO yet.
